Many cancer drugs remain unproven 5 years after accelerated approval, says Study
The promise of early access to potentially life-saving drugs through the US Food and Drug Administration’s accelerated approval program often comes with high hopes for patients battling debilitating or fatal diseases. However, a recent study sheds light on the reality that many of these drugs fail to demonstrate significant benefits within a reasonable timeframe.
Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania, underscores the urgency of obtaining definitive answers about the efficacy of accelerated approval drugs within five years. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not,” he emphasizes.
Facebook Comments
